Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2005, p. 1531-1537, Vol. 43, No. 4
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.4.1531-1537.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
os,1
Julia Lee,
Maureen McTeague,2 and
Sydney M. Finegold3,4,5
Research Service,1 Clinical Microbiology Laboratory,2 Infectious Diseases Section, VA Medical Center West Los Angeles,3 Department of Medicine ,4 Department of Microbiology, Immunology, and Molecular Genetics, UCLA School of Medicine, Los Angeles, California5
Received 30 August 2004/ Returned for modification 5 October 2004/ Accepted 5 November 2004
|
|
|---|
|
|
|---|
Several identification systems are available commercially for the rapid identification of anaerobes. However, these systems are designed to identify as wide a range of anaerobes as possible, and they contain many tests of little relevance for identification of Bacteroides species. Furthermore, databases accompanying the kits are often incomplete or inaccurate, especially with a number of newly described species. A short biochemical scheme described in the Wadsworth-KTL Anaerobic Bacteriology Manual (13) was developed specifically for the identification of B. fragilis group species. It involves the minimum essential biochemical tests, thus providing clinical laboratories with an inexpensive and simple alternative for the identification of these bacteria. However, a recent study indicated that this biochemical scheme was not as accurate as a multiplex PCR identification scheme established in that study (14).
Direct sequencing of the PCR-amplified bacterial 16S rRNA gene is one of the new molecular identification methods. It has been used in identification of bacteria of many types (2, 5, 6, 11, 12, 16, 18, 21, 23, 24) and unidentified clinical bacterial isolates (7, 25). In this study, we evaluated the suitability of 16S rRNA gene sequencing for the identification of clinically significant Bacteroides species. Furthermore, using 16S rRNA gene sequencing as a standard, we have also analyzed previous errors with the biochemical scheme and modified it for more accurate identification of this group of bacteria.
|
|
|---|
-fucosidase or ß-glucuronidase was tested with Rosco diagnostic tablets (Taastrup, Denmark). Sugar fermentation tests were performed with PRAS peptone-yeast-sugar broth tubes (Anaerobe Systems). Briefly, the PRAS tubes were inoculated from an actively growing broth culture (without carbohydrate). After incubation at 37°C until good growth was seen (of at least 2+ turbidity), the pH was measured with a pH meter. Identifications were counted as correct if both the biochemical and 16S rRNA gene sequencing methods provided the same answer. A discordant result was defined as a 16S rRNA sequence match with a species other than the species assigned by phenotypic identification. For the strains with discrepant identification, the phenotypic tests mentioned above were repeated, and the strains were also examined with commercially available API ZYM and rapid ID 32A (bioMérieux, Marcy l'Etoile, France), RapID ANA II (Remel, Inc., Lenexa, Kans.), and BBL Crystal Identification (Becton Dickinson Microbiology Systems, Cockeysville, Md.) systems, according to the respective manufacturer's instructions. |
View this table: [in a new window] |
TABLE 1. List of strains used in this study
|
Sequence data analysis. The sequencing data were analyzed by (i) assembly of the reverse and forward sequences into a consensus sequence, (ii) editing of the consensus sequence to resolve discrepancies between the two strands by evaluation of the electropherograms, and (iii) comparison of the consensus sequences with GenBank sequences by using the Ribosomal Database Project (RDP-II) (Michigan State University, East Lansing, Mich.) (15) and the Basic Local Alignment Search Tool (BLAST) (1). Analysis of Bacteroides clinical isolates was performed by comparing the sequences against the sequences of type strains determined in this study as well as related sequences retrieved from GenBank.
|
|
|---|
99%) with sequences of their corresponding strains from GenBank as determined by both BLAST and RDP-II. Of the 231 clinical strains, 192 strains had a sequence with high similarity (
99%) to an established species. Twenty strains had high sequence similarities to two uncharacterized strains in GenBank; these included 7 isolates of B. merdae and 13 isolates of B. stercoris, originally identified by phenotypic testing, that were determined to be 99% similar to 16S rRNA gene sequences of two uncharacterized strains, Bacteroides sp. ASF519 and bacterium strain 31285, respectively. They had only 94.0 and 95% similarities to B. merdae and B. stercoris, respectively (novel species groups IV and II) (Table 2). The remaining 19 strains had three unique sequences that were distinct (similarity,
96%) from any sequence in the GenBank database (novel species groups I, III, and V) (Table 2). These were assigned a phylogenetic position by construction of a phylogenetic tree with their related sequences (Fig. 1). |
View this table: [in a new window] |
TABLE 2. Comparison of 16S rRNA sequencing identification with phenotypic identification
|
![]() View larger version (36K): [in a new window] |
FIG. 1. The phylogenetic tree indicates the phylogenetic relationship of the five possible novel species with their related established species, including one representative strain for each species. The tree was rooted using Chlorobium vibrioforme DSM 260T (M62791) as the outgroup sequence. The closest phylogenetically valid species to novel species groups I and II is B. thetaiotaomicron (96%). The closest valid species to novel species groups III, IV, and V are B. ovatus (93%), B. merdae (94.0%), and Alistipes massiliensis (96%), respectively. NOvel species groups I and II have recently been proposed as B. sulyersiae and B. nordii, respectively.
|
Analysis of failures and modification of the biochemical scheme.
The established biochemical scheme for identification of B. fragilis group species was reevaluated by comparison with 16S rRNA gene sequence analysis of 231 clinical isolates that were previously identified to the species level by this scheme. The key phenotypic characteristics on the flow chart of the biochemical scheme were retested for the 59 strains that had discordant identifications between 16S rRNA gene sequencing and the biochemical scheme; the results are shown in Table 3. For the 20 strains that were reidentified as a different valid Bacteroides species by 16S rRNA gene sequencing, 4 were strains of B. ovatus misidentified as B. caccae because of a false-negative spot indole test; they were indole positive only by the tube test. For the sugar fermentation tests, a pH of
5.5 in the PRAS tubes was interpreted as acid (positive), 5.6 to 5.8 was interpreted as weakly acid (weak positive), and
5.9 was interpreted as negative fermentation. Seven strains of B. thetaiotaomicron were misidentified as B. ovatus because of the unmatched xylan fermentation profile; they had pHs near 5.5 (range, 5.3 to 5.6) in the xylan reaction. They were interpreted as xylan positive and therefore were misidentified as B. ovatus. Similarly, nine strains of B. uniformis were misidentified as B. thetaiotaomicron because of the unmatched trehalose fermentation profile; their reactions with trehalose were interpreted as positive (pH range, 5.4 to 5.6), in contrast to the negative status in the flow chart. Further characterization of these strains by biochemical kits showed that arginine arylamidase and leucine arylamidase could be used to separate xylan-positive B. thetaiotaomicron (both arginine arylamidase and leucine arylamidase are positive) from B. ovatus (both are negative), and trehalose-positive B. uniformis (both are negative) from B. thetaiotaomicron. For the other 39 strains that may represent five novel species by 16S rRNA gene sequence analysis, phenotypic tests were carried out to characterize and distinguish them from the species they resembled. For example,
-fucosidase,
-arabinosidase, and
-chymotrypsinase could be used to distinguish group I novel species from B. uniformis; glutamic acid decarboxylase, arginine dihydrolase, and p-nitrophenyl-ß,D-disaccharidase could differentiate group II novel species from B. stercoris. Glutamyl glutamic acid arylamidase and pyrrolidonyl arylamidase could be used to separate group III and IV species from the biochemically similar B. ovatus and B. merdae, respectively (Table 3). According to the results we obtained from this study, the biochemical scheme was modified and is shown in Fig. 2.
|
View this table: [in a new window] |
TABLE 3. Key characteristics to distinguish misidentified species or novel species from the species they resemble phenotypicallya
|
![]() View larger version (17K): [in a new window] |
FIG. 2. Flow chart illustrating modified scheme for identification of B. fragilis group and related Bacteriodes spp. Adapted from the flow chart in reference 13 with permission of the publisher. Boldface type indicates the changes made in this study from our original flow chart (13). Indolea, the indole test should be performed by the PRAS tube test; Arga, arginine arylamidase (tested by rapid ID 32A); GGA, glutamyl glutamic acid arylamidase (tested by rapid ID 32A); FPY, pyrrolidonyl arylamidase (tested with BBL Crystal Identification systems); -ARA, -arabinosidase (tested by RapidID 32A).
|
|
|
|---|
16S rRNA gene sequencing has been widely used for bacterial identification. The large rRNA sequence databases at GenBank and at RDP-II allow for a quick comparison of 16S ribosomal DNA (rRNA gene) sequences and to provide phylogenetically useful information, even if a particular sequence has no match in the database. However, its use for species identification is not without limitations. For example, there is no accepted cutoff value of 16S rRNA sequence similarity for species definition (17, 22). Studies of numerous diverse taxa clearly indicated that the majority of recognized species that have been examined to date differ in their 16S rRNA sequences from related species of the same genus in at least 1% of the sequence positions, and typically by more. Our 16S rRNA sequence data showed that the recognized species within the Bacteroides phylogenetic cluster (which excludes B. merdae and B. distasonis) has up to 7.0% or more average divergence. This indicates clearly that the species of the Bacteroides genus are typically separated by good evolutionary distances. All the isolates within the same species shared
99% sequence similarity with their corresponding type strains except for 32 isolates of the B. fragilis species, which fell into two clusters with approximately 1.5% difference between them. One cluster shared
99% sequence similarity with that of B. fragilis strain ATCC 25285T, and the other cluster had a high similarity (
99%) with that of B. fragilis strain 2393. These variations might be attributed to intraspecies heterogeneity, but it also suggests that they may in fact be new species. Since there is no clear cutoff value for species assignment, in this study we decided to use stringent criteria (
99% similarity) for species identification. If an isolate showed a genetic difference of
1.00 and
2.00%, we reported it as closely related to its best match; thus, the 21 isolates that had a 98.6% sequence similarity with the B. fragilis type strain might be the same species or a subspecies of B. fragilis. In cases where the genetic difference was >2%, the isolate was reported as a unique isolate that may represent a novel taxon (Table 2). The reason that we used only type strains was to eliminate any possible errors of species identification due to initial strain misidentification.
The other issue is the quality of public databases such as GenBank. It is commonly known that sequences are deposited in these databases largely independent of their quality, e.g., the number of ambiguous nucleotides, sequence gaps and errors, and the length of the sequence. Therefore, caution was exercised when we carried out the sequence analysis for species identification. Analysis of Bacteroides clinical isolates was performed by comparing the sequences against related sequences retrieved from GenBank as well as against the sequences of type strains determined in this study. In addition, for an accurate determination of species similarities, all 5' and 3' ends of the sequences were cut at identical positions along the gene, at Escherichia coli bp 49 to 1450, and the sequences determined in this study and their corresponding sequences in GenBank were aligned and manually analyzed.
Despite some unresolved issues in 16S rRNA gene sequencing for microbial identification, the advantages of this technique outweigh its limitations, in general. It provides more accurate, more objective, and comprehensive species concepts. Signature nucleotides of 16S rRNA genes allow the determination of phylogenetic relationships among the bacteria that would not have resulted from phenotypic data alone. In this study, we encountered five groups of clinical isolates that may represent five novel taxa. Two of them (novel species groups I and II) have been described recently as B. salyersiae and B. nordii, respectively; further characterization of the other three groups will be carried out. Systematic description of new bacterial species recovered from patients may contribute to the description of emerging infections. Therefore efforts should be made to report the possible novel species, even if only very few strains have been isolated. The strains should be deposited in an international collection and the sequence should be accessible through public databases. This will allow further definition of their clinical significance.
Although the idea that 16S rRNA gene sequencing could be used for bacterial identification of cultured bacteria has become increasingly realistic, the cost is still a critical issue in the evaluation of 16S rRNA gene sequence analysis as a diagnostic tool in clinical laboratories. Therefore, in this study, based on solid identification obtained from sequencing, we reevaluated and modified the biochemical flow chart.
Citron et al. (4) have developed a short biochemical scheme for identification of Bacteroides species. This scheme involves the minimum essential biochemical tests and only requires overnight incubation; therefore, it provides a rapid, cost-effective, and simple alternative for the identification of these bacteria. However, this scheme possesses the limitations of all biochemical identification schemes, such as the fact that phenotypic characteristics of clinical isolates are not always typical and may lead to ambiguous results; interpretation of test results involves substantial subjective judgment. Especially with those newly encountered novel species, the scheme is not sufficient to distinguish them from the others. For example, we found that 7 of 26 B. thetaiotaomicron and 9 of 21 B. uniformis isolates had pHs near 5.5 with reactions to xylan and trehalose, respectively, and were thus interpreted as xylan or trehalose positive and misidentified as B. ovatus and B. thetaiotaomicron, respectively. This indicated that xylan and trehalose fermentation tests are not reliable for making distinctions among these species. Further tests showed that arginine arylamidase and leucine arylamidase could be used to distinguish these species (Table 3 and Fig. 2). Furthermore, since 4 of 21 B. ovatus strains gave a false-negative spot indole test, we suggest that the tube indole test should be used instead of the spot indole test. The key characteristics distinguishing the possible novel species from the other Bacteroides species were added to a biochemical flow chart that we have previously published (Fig. 2) (13).
In summary, the overall performance of 16S rRNA gene sequencing for Bacteroides species identification was excellent. However, since 16S rRNA gene sequencing is not used routinely in clinical microbial identification, we have improved the short biochemical scheme based on the solid identification we obtained from sequencing to provide clinical laboratories with an inexpensive and simple alternative.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»